iShares MSCI Australia ETF vs Eli Lilly And Co — how do they compare? iShares MSCI Australia ETF trades at $29.94, while Eli Lilly And Co trades at $1,214.99 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals.
| EWA | LLY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $1.24K |
52-Week Low | $24.95 | $639.43 |
Market Cap | — | $1.10T |
Enterprise Value | — | $1.14T |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.
Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →